Biomarkers of risk stratification in congestive heart failure: North American view

Biomarkers in Medicine

Volumn 3, Issue 5, 2009, Pages 443-452

  Tang, W H Wilson ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Biomarkers; Heart failure; Natriuretic peptide; Risk stratification; Troponin

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; MYELOPEROXIDASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ROSUVASTATIN; TOLVAPTAN; TROPONIN I; TROPONIN T; URIC ACID; VASOPRESSIN RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; ANEMIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; ELECTROLYTE DISTURBANCE; ERYTHROCYTE SEDIMENTATION RATE; GENETIC SCREENING; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HUMAN; HYPONATREMIA; MEDICAL DECISION MAKING; MORTALITY; MUTATIONAL ANALYSIS; NORTH AMERICA; PATHOPHYSIOLOGY; PREDICTION; PROGNOSIS; REVIEW; RISK ASSESSMENT; SYSTOLIC HEART FAILURE; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL;

EID: 70450286286     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.09.52     Document Type: Review

References (77)

1. Velagaleti RS, Pencina MJ, Murabito JM et al.: Long-term trends in the incidence of heart failure after myocardial infarction. Circulation 118, 2057-2062 (2008).
2. Jessup M, Abraham WT, Casey DE et al.: 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119, 1977-2016 (2009).
3. deFilippi CR, Seliger SL: Biomarkers for prognostication after acute coronary syndromes: new times and statistics. J. Am. Coll. Cardiol. 54, 365-367 (2009).
4. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC: Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J. Am. Coll. Cardiol. 43, 1439-1444 (2004). (Pubitemid 38496352)
5. Tang WH, Francis GS, Morrow DA et al.: National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 116, E99-E109 (2007). • Guidelines from the National Academy of Clinical Biochemistry with a comprehensive review and recommendations regarding the clinical applications of biomarkers in heart failure.
6. Heart Failure Society of America: Evaluation of patients for ventricular dysfunction and heart failure. J. Card. Fail. 12, E16-E25 (2006).
7. Maisel AS, Krishnaswamy P, Nowak RM et al.: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 347, 161-167 (2002).
8. Januzzi JL Jr, Camargo CA, Anwaruddin S et al.: The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am. J. Cardiol. 95, 948-954 (2005). (Pubitemid 40487743)
9. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M: Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J. Am. Coll. Cardiol. 49, 1943-1950 (2007).
10. Januzzi JL Jr, Sakhuja R, O'Donoghue M et al.: Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch. Intern. Med. 166, 315-320 (2006). (Pubitemid 43244319)
11. Moe GW, Howlett J, Januzzi JL, Zowall H: N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 115, 3103-3110 (2007). (Pubitemid 46956499)
12. Mueller C, Scholer A, Laule-Kilian K et al.: Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N. Engl. J. Med. 350, 647-654 (2004).
13. Singer AJ, Birkhahn RH, Guss D et al.: Rapid Emergency Department Heart Failure Outpatients Trial (REDHOT II): a randomized controlled trial of the effect of serial BNP testing on patient management. Circ. Heart Fail. doi: 10.1161/CIRCHEARTFAILURE.108.826685 (2009) (Epub ahead of print).
14. Schneider HG, Lam L, Lokuge A et al.: B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients with dyspnea: a randomized trial. Ann. Intern. Med. 150, 365-371 (2009).
15. O'Neill JO, Bott-Silverman CE, McRae AT 3rd et al.: B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. Am. Heart J. 149, 363-369 (2005).
16. Shah MR, Hasselblad V, Tasissa G et al.: Rapid assay brain natriuretic peptide and troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial). Am. J. Cardiol. 100, 1427-1433 (2007).
17. Mehra MR, Uber PA, Park MH et al.: Obesity and suppressed B-type natriuretic peptide levels in heart failure. J. Am. Coll. Cardiol. 43, 1590-1595 (2004).
18. Taylor JA, Christenson RH, Rao K, Jorge M, Gottlieb SS: B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am. Heart J. 152, 1071-1076 (2006). (Pubitemid 44854793)
19. Troughton RW, Prior DL, Pereira JJ et al.: Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J. Am. Coll. Cardiol. 43, 416-422 (2004).
20. Tang WH, Girod JP, Lee MJ et al.: Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 108, 2964-2966 (2003).
21. James KB, Troughton RW, Feldschuh J, Soltis D, Thomas D, Fouad-Tarazi F: Blood volume and brain natriuretic peptide in congestive heart failure: a pilot study. Am. Heart J. 150, 984 (2005).
22. van Kimmenade RR, Januzzi JL Jr, Bakker JA et al.: Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J. Am. Coll. Cardiol. 53, 884-890 (2009).
23. Hogenhuis J, Voors AA, Jaarsma T, Hillege HL, Boomsma F, van Veldhuisen DJ: Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT-ANP and BNP/NT-proBNP. Eur. J. Heart Fail. 7, 81-86 (2005). (Pubitemid 40092496)
24. Pfisterer M, Buser P, Rickli H et al.: BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301, 383-392 (2009).
25. Jourdain P, Jondeau G, Funck F et al.: Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J. Am. Coll. Cardiol. 49, 1733-1739 (2007). (Pubitemid 46589928)
26. Peacock WFt, De Marco T, Fonarow GC et al.: Cardiac troponin and outcome in acute heart failure. N. Engl. J. Med. 358, 2117-2126 (2008). (Pubitemid 351679598)
27. Cardinale D, Sandri MT, Colombo A et al.: Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109, 2749-2754 (2004). (Pubitemid 38737923)
28. Cardinale D, Colombo A, Sandri MT et al.: Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114, 2474-2481 (2006). •• Insightful series of patients receiving high-dose chemotherapy, demonstrating the potential for biomarker-guided indications to prevent heart failure and cardiac dysfunction.
29. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ: Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293, 572-580 (2005).
30. Filippatos G, Rossi J, Lloyd-Jones DM et al.: Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. J. Card. Fail. 13, 360-364 (2007). (Pubitemid 46977793)
31. Forman DE, Butler J, Wang Y et al.: Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J. Am. Coll. Cardiol. 43, 61-67 (2004). (Pubitemid 38045917)
32. Gottlieb SS, Abraham W, Butler J et al.: The prognostic importance of different definitions of worsening renal function in congestive heart failure. J. Card. Fail. 8, 136-141 (2002). (Pubitemid 34857278)
33. Pilz S, Marz W, Wellnitz B et al.: Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J. Clin. Endocrinol. Metab. 93, 3927-3935 (2008).
34. Gheorghiade M, Rossi JS, Cotts W et al.: Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Arch. Intern. Med. 167, 1998-2005 (2007).
35. Packer M, Lee WH, Kessler PD, Medina N, Yushak M, Gottlieb SS: Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. J. Am. Coll. Cardiol. 10, 837-844 (1987).
36. Rossi J, Bayram M, Udelson JE et al.: Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card. Care 9, 82-86 (2007).
37. Konstam MA, Gheorghiade M, Burnett JC Jr et al.: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297, 1319-1331 (2007). (Pubitemid 46513233)
38. Paterna S, Di Pasquale P, Parrinello G et al.: Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. J. Am. Coll. Cardiol. 45, 1997-2003 (2005).
39. Anand IS, Florea VG: High output cardiac failure. Curr. Treat. Options Cardiovasc. Med. 3, 151-159 (2001).
40. Tang WH: Anemia in heart failure: current evidence and challenges. Rev. Cardiovasc. Med. 8, 78-86 (2007).
41. Tang WH, Tong W, Jain A, Francis GS, Harris CM, Young JB: Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J. Am. Coll. Cardiol. 51, 569-576 (2008).
42. Felker GM, Allen LA, Pocock SJ et al.: Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM program and the Duke databank. J. Am. Coll. Cardiol. 50, 40-47 (2007).
43. Wood P: The erythrocyte sedimentation rate in diseases of the heart. Q. J. Med. 5, 1-19 (1939).
44. Petersen JW, Felker GM: Inflammatory biomarkers in heart failure. Congest. Heart Fail. 12, 324-328 (2006).
45. Anand IS, Latini R, Florea VG et al.: C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 112, 1428-1434 (2005). (Pubitemid 41291768)
46. Tang WH, Shrestha K, Van Lente F et al.: Usefulness of C-reactive protein and left ventricular diastolic performance for prognosis in patients with left ventricular systolic heart failure. Am. J. Cardiol. 101, 370-373 (2008). (Pubitemid 351162964)
47. Tang WH, Brennan ML, Philip K et al.: Plasma myeloperoxidase levels in patients with chronic heart failure. Am. J. Cardiol. 98, 796-799 (2006). (Pubitemid 44301017)
48. Tang WH, Tong W, Troughton RW et al.: Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J. Am. Coll. Cardiol. 49, 2364-2370 (2007). (Pubitemid 46891707)
49. Mocatta TJ, Pilbrow AP, Cameron VA et al.: Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J. Am. Coll. Cardiol. 49, 1993-2000 (2007).
50. Tang WH, Tong W, Troughton RW et al.: Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J. Am. Coll. Cardiol. 49, 2364-2370 (2007). (Pubitemid 46891707)
51. Kardys I, Knetsch AM, Bleumink GS et al.: C-reactive protein and risk of heart failure. The Rotterdam Study. Am. Heart J. 152, 514-520 (2006). (Pubitemid 44233424)
52. Ng LL, Pathik B, Loke IW, Squire IB, Davies JE: Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am. Heart J. 152, 94-101 (2006). (Pubitemid 43974728)
53. Tang WH, Katz R, Brennan ML et al.: Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure. Am. J. Cardiol. 103, 1269-1274 (2009).
54. Vasan RS, Sullivan LM, Roubenoff R et al.: Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107, 1486-1491 (2003).
55. Leyva F, Anker SD, Godsland IF et al.: Uric acid in chronic heart failure: a marker of chronic inflammation. Eur. Heart J. 19, 1814-1822 (1998).
56. Anker SD, Doehner W, Rauchhaus M et al.: Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 107, 1991-1997 (2003).
57. Hare JM, Mangal B, Brown J et al.: Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J. Am. Coll. Cardiol. 51, 2301-2309 (2008). (Pubitemid 351783365)
58. Crispell KA, Hanson EL, Coates K, Toy W, Hershberger RE: Periodic rescreening is indicated for family members at risk of developing familial dilated cardiomyopathy. J. Am. Coll. Cardiol. 39, 1503-1507 (2002). (Pubitemid 34439067)
59. Tang WH: Natriuretic peptide measurements in managing heart failure: in theory and in practice. Circ. Heart Fail. 2, 380-381 (2009).
60. Boisot S, Beede J, Isakson S et al.: Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J. Card. Fail. 14, 732-738 (2008).
61. Januzzi JL Jr, Peacock WF, Maisel AS et al.: Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J. Am. Coll. Cardiol. 50, 607-613 (2007).
62. Rehman SU, Mueller T, Januzzi JL Jr: Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J. Am. Coll. Cardiol. 52, 1458-1465 (2008).
63. Milting H, Ellinghaus P, Seewald M et al.: Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J. Heart Lung Transplant. 27, 589-596 (2008). (Pubitemid 351715387)
64. van Kimmenade RR, Januzzi JL Jr, Ellinor PT et al.: Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J. Am. Coll. Cardiol. 48, 1217-1224 (2006).
65. Radauceanu A, Ducki C, Virion JM et al.: Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J. Card. Fail. 14, 467-474 (2008). (Pubitemid 352040864)
66. Kempf T, von Haehling S, Peter T et al.: Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J. Am. Coll. Cardiol. 50, 1054-1060 (2007). (Pubitemid 47348231)
67. Dieplinger B, Gegenhuber A, Haltmayer M, Mueller T: Evaluation of novel biomarkers for the diagnosis of acute destabilized heart failure in shortness-of-breath patients. Heart doi: 10.1136/hrt.2009.170696 (2009) (Epub ahead of print).
68. Voors AA, von Haehling S, Anker SD et al.: C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur. Heart J. 30, 1187-1194 (2009).
69. Tang WH, Wang Z, Cho L, Brennan DM, Hazen SL: Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J. Am. Coll. Cardiol. 53, 2061-2067 (2009).
70. Tang WH, Tong W, Shrestha K et al.: Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. Eur. Heart J. 29, 2506-2513 (2008).
71. Wei YJ, Huang YX, Zhang XL et al.: Apolipoprotein D as a novel marker in human end-stage heart failure: a preliminary study. Biomarkers 13, 535-548 (2008).
72. Wedel H, McMurray JJ, Lindberg M et al.: Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur. J. Heart Fail. 11, 281-291 (2009).
73. Hershberger RE, Lindenfeld J, Mestroni L, Seidman CE, Taylor MR, Towbin JA: Genetic evaluation of cardiomyopathy - a Heart Failure Society of America practice guideline. J. Card. Fail. 15, 83-97 (2009).
74. 1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. Proc. Natl Acad. Sci. USA 103, 11288-11293 (2006).
75. Taylor MR, Slavov D, Humphrey K et al.: Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure. Pharmacogenet. Genomics 19, 35-43 (2009).
76. McNamara DM, Holubkov R, Postava L et al.: Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J. Am. Coll. Cardiol. 44, 2019-2026 (2004). (Pubitemid 39473288)
77. McKie PM, Rodeheffer RJ, Cataliotti A et al.: Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 47, 874-880 (2006). (Pubitemid 44297558)